恩替卡韦联合扶正化瘀胶囊治疗HBeAg阳性的慢性乙型病毒性肝炎的疗效  

Clinical observation of entecavir combined with Fuzheng Huayu capsules in the treatment of HBeAg positive chronic hepatitis B with blood stasis obstruction type

作　　者：蓝柏钊 陈辛酉 林嘉欣 周甦 钟大明 莫穆隆 Lan Bozhao;Chen Xinyou;Lin Jiaxin;Zhou Su;Zhong Daming;Mo Mulong(The Third People's Hospital of Wuzhou,Wuzhou 543000,China)

机构地区：[1]广西省梧州市第三人民医院,543000

出　　处：《现代养生》2023年第24期1887-1890,共4页Health Protection and Promotion

摘　　要：目的 通过临床对比分析,观察恩替卡韦联合扶正化瘀胶囊治疗瘀血阻络型HBeAg阳性的慢性乙型病毒性肝炎的临床疗效,为临床决策提供参考。方法 以梧州市第三人民医院肝病科收治的110例瘀血阻络型HBeAg阳性慢性乙型病毒性肝炎初治患者为研究对象,根据组间基线资料均衡可比的原则分为观察组53例和对照组57例。对照组采用恩替卡韦治疗,观察组在对照组基础上加用扶正化瘀胶囊治疗。对比两组患者的总胆红素(TBIL)、直接胆红素(DBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、乙型肝炎病毒表面抗原(HBsAg)的水平;乙肝病毒基因(HBV-DNA)转阴率、乙肝病毒e抗原(HBeAg)转换率;不良反应发生率。结果 治疗后,两组患者TBIL、DBIL、ALT、AST、HBsAg载量均明显下降,其中观察组患者HBV-DNA阴转率、HBsAg载量、ALT水平低于对照组,差异有统计学意义(P<0.05);但两组患者TBIL、DBIL、AST水平比较,差异无统计学意义(P>0.05)。治疗后,观察组患者HBeAg转换率高于对照组,但组间差异无统计学意义(P>0.05)。治疗期间观察组患者不良反应发生率为5.26%,高于对照组的3.77%,但差异无统计学意义(P>0.05)。结论 对于瘀血阻络型HBeAg阳性慢性乙型病毒性肝炎患者,恩替卡韦联合扶正化瘀胶囊治疗可降低患者HBV-DNA阴转率及HBsAg、ALT载量,明显优于单独使用恩替卡韦的治疗效果。Objective Evaluation of the clinical efficacy of entecavir combined with Fuzheng Huayu capsules in the treatment of chronic hepatitis B with HBeAg positive blood stasis obstruction type.Methods 110 patients with HBeAG-positive chronic viral hepatitis B treated in Wuzhou Third People's Hospital were divided into observation group(53 cases)and control group(57 cases)according to the principle of balanced and comparable baseline data.The control group was treated with entecavir,and the observation group was treated with Fuzheng Huayu capsules on the basis of control group.The levels of total bilirubin(TBIL),direct bilirubin(DBIL),alanine aminotransferase(ALT),aspartate aminotransferase(AST)and hepatitis B virus surface antigen(HBsAg)were compared between the two groups.Hepatitis B virus gene(HBV-DNA)negative conversion rate,Hepatitis B virus e antigen(HBeAg)conversion rate;And the incidence of adverse reactions.Results After treatment,the loads of TBIL,DBIL,ALT,AST and HBsAg decreased significantly in both groups.The negative rate of HBV-DNA,HBsAg load and ALT level in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).There was no significant difference in TBIL,DBIL and AST between the two groups(P>0.05).The negative conversion rate of HBV-DNA in observation group was better than that in control group,and the difference was statistically significant(P<0.05).The HBeAg conversion rate of observation group was higher than that of control group,but there was no significant difference between groups(P>0.05).The incidence of adverse reactions in the observation group was 5.26%,higher than that in the control group(3.77%),but the difference was not statistically significant(P>0.05).Conclusion For patients with HBeAg-positive chronic hepatitis B due to blood stasis,entecavir combined with Fuzhenghuayu capsules can reduce HBV-DNA negative conversion rate and HBsAg and ALT load,which is obviously better than entecavir alone.

关 键 词：慢性乙型肝炎 恩替卡韦 瘀血阻络 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]